FI973733A0 - Farmaceutiskt preparat och foerfarande foer dess framstaellning - Google Patents

Farmaceutiskt preparat och foerfarande foer dess framstaellning

Info

Publication number
FI973733A0
FI973733A0 FI973733A FI973733A FI973733A0 FI 973733 A0 FI973733 A0 FI 973733A0 FI 973733 A FI973733 A FI 973733A FI 973733 A FI973733 A FI 973733A FI 973733 A0 FI973733 A0 FI 973733A0
Authority
FI
Finland
Prior art keywords
pharmaceutical preparations
oral
hypocalcemic
clodronate
salt
Prior art date
Application number
FI973733A
Other languages
English (en)
Other versions
FI973733A (fi
FI109088B (fi
Inventor
Veli-Matti Lehtola
Eeva-Maria Susanne Rantala
Pertti Tapani Rantala
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Publication of FI973733A0 publication Critical patent/FI973733A0/fi
Priority to FI973733A priority Critical patent/FI109088B/fi
Priority to UA2000042105A priority patent/UA73078C2/uk
Priority to SI9830599T priority patent/SI1027037T1/xx
Priority to KR1020007002955A priority patent/KR20010024184A/ko
Priority to PT98945336T priority patent/PT1027037E/pt
Priority to DE1027037T priority patent/DE1027037T1/de
Priority to DE69820287T priority patent/DE69820287T2/de
Priority to EEP200000096A priority patent/EE04218B1/xx
Priority to AU92685/98A priority patent/AU737738B2/en
Priority to TR2000/00722T priority patent/TR200000722T2/xx
Priority to JP2000512526A priority patent/JP3589977B2/ja
Priority to IL13513098A priority patent/IL135130A/en
Priority to DE29824938U priority patent/DE29824938U1/de
Priority to ES98945336T priority patent/ES2212341T3/es
Priority to DK98945336T priority patent/DK1027037T3/da
Priority to SK393-2000A priority patent/SK284088B6/sk
Priority to CA002301185A priority patent/CA2301185C/en
Priority to CZ20000787A priority patent/CZ298675B6/cs
Priority to CN98809173A priority patent/CN1124130C/zh
Priority to PCT/FI1998/000735 priority patent/WO1999015155A1/en
Priority to BR9812480-3A priority patent/BR9812480A/pt
Priority to EP98945336A priority patent/EP1027037B1/en
Priority to AT98945336T priority patent/ATE255410T1/de
Priority to NZ503766A priority patent/NZ503766A/en
Priority to EA200000317A priority patent/EA002331B1/ru
Priority to HU0004383A priority patent/HU226118B1/hu
Priority to PL339290A priority patent/PL191166B1/pl
Priority to IDW20000735A priority patent/ID24423A/id
Publication of FI973733A publication Critical patent/FI973733A/fi
Priority to HR20000142A priority patent/HRP20000142B1/xx
Priority to IS5404A priority patent/IS5404A/is
Priority to NO20001417A priority patent/NO327728B1/no
Priority to BG104265A priority patent/BG64886B1/bg
Priority to HK01100766A priority patent/HK1031325A1/xx
Application granted granted Critical
Publication of FI109088B publication Critical patent/FI109088B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI973733A 1997-09-19 1997-09-19 Tabletti ja menetelmä sen valmistamiseksi FI109088B (fi)

Priority Applications (33)

Application Number Priority Date Filing Date Title
FI973733A FI109088B (fi) 1997-09-19 1997-09-19 Tabletti ja menetelmä sen valmistamiseksi
CA002301185A CA2301185C (en) 1997-09-19 1998-09-18 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
CN98809173A CN1124130C (zh) 1997-09-19 1998-09-18 含氯甲双磷酸盐活性成分和硅化微晶纤维素赋形剂的药物制剂
KR1020007002955A KR20010024184A (ko) 1997-09-19 1998-09-18 활성 성분으로 클로드로네이트, 부형제로 실리시파이드미세결정성 셀룰로즈를 함유하는 의약 제제
SI9830599T SI1027037T1 (en) 1997-09-19 1998-09-18 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
DE1027037T DE1027037T1 (de) 1997-09-19 1998-09-18 Arzneimittel, das clodronat als wirkstoff und mit siliciumdioxid behandelte mikrokristalline cellulose als füllsstoff enhält
PCT/FI1998/000735 WO1999015155A1 (en) 1997-09-19 1998-09-18 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
EEP200000096A EE04218B1 (et) 1997-09-19 1998-09-18 Toimeainena klodronaati ja ekstsipiendina ränistatud mikrokristallilist tselluloosi sisaldav farmatseutiline preparaat ning farmatseutilise preparaadi tootmismeetod
AU92685/98A AU737738B2 (en) 1997-09-19 1998-09-18 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
TR2000/00722T TR200000722T2 (tr) 1997-09-19 1998-09-18 Silikatlı küçük kristalli selüloz içeren farmakolojik ilaç.
JP2000512526A JP3589977B2 (ja) 1997-09-19 1998-09-18 活性成分としてクロドロン酸塩および賦形剤としてケイ化微晶質セルロースを含む医薬製剤
IL13513098A IL135130A (en) 1997-09-19 1998-09-18 A pharmaceutical preparation containing claudronate as an active ingredient and microcrystalline cellulose that has undergone silification as an excipient
DE29824938U DE29824938U1 (de) 1997-09-19 1998-09-18 Pharmazeutische Zubereitung, die Clodronat als Wirkstoff und silifizierte mikrokristalline Cellulose als Exzipienten umfasst
ES98945336T ES2212341T3 (es) 1997-09-19 1998-09-18 Preparacion farmaceutica que comprende clodronato como ingrediente activo y celulosa microcristalina modificada con silice como excipiente.
DK98945336T DK1027037T3 (da) 1997-09-19 1998-09-18 Farmaceutisk præparat som indeholder clodronat som aktiv ingrediens og forkislet mikrokrystallinsk cellulose som excipiens
SK393-2000A SK284088B6 (sk) 1997-09-19 1998-09-18 Farmaceutický prostriedok obsahujúci klodronát ako aktívne činidlo, spôsob výroby prostriedku a použitie mikrokryštalickej celulózy na jeho výrobu
UA2000042105A UA73078C2 (uk) 1997-09-19 1998-09-18 Фармацевтичний препарат у вигляді таблеток на основі солі дихлорметилендифосфорної кислоти та силікатованої мікрокристалічної целюлози та спосіб його одержання
CZ20000787A CZ298675B6 (cs) 1997-09-19 1998-09-18 Farmaceutický prostredek obsahující klodronát a mikrokrystalickou celulózu s oxidem kremicitým
PT98945336T PT1027037E (pt) 1997-09-19 1998-09-18 Composicao farmaceutica que compreende clodronato como ingredientes activo e celulose microcristalina silicificada como excipiente
DE69820287T DE69820287T2 (de) 1997-09-19 1998-09-18 Pharmazeutische Zubereitung, die Chlodronat als Wirkstoff und silicifizierte mikrokristalline Cellulose als Exipienten umfasst
BR9812480-3A BR9812480A (pt) 1997-09-19 1998-09-18 "preparação farmacêutica compreendendo clodronato como ingrediente ativo e celulose microcristalina como excipiente, processo de fabricação e uso de celulose microcristalina siliciada na fabricação de dita preparação farmacêutica"
EP98945336A EP1027037B1 (en) 1997-09-19 1998-09-18 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
AT98945336T ATE255410T1 (de) 1997-09-19 1998-09-18 Arzneimittel, das clodronat als wirkstoff und mit siliciumdioxid behandelte mikrokristalline cellulose als füllstoff enthält
NZ503766A NZ503766A (en) 1997-09-19 1998-09-18 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
EA200000317A EA002331B1 (ru) 1997-09-19 1998-09-18 Фармацевтический препарат, содержащий клодронат в качестве активного ингредиента и агрегат микрокристаллической целлюлозы и диоксида кремния в качестве наполнителя
HU0004383A HU226118B1 (en) 1997-09-19 1998-09-18 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
PL339290A PL191166B1 (pl) 1997-09-19 1998-09-18 Preparat farmaceutyczny zawierający klodronian, sposób jego wytwarzania i zastosowanie krzemionkowanej celulozy mikrokrystalicznej
IDW20000735A ID24423A (id) 1997-09-19 1998-09-18 Sediaan farmasi yang terdiri dari klodronat sebagai bahan aktif dan selulosa mikrokristalin tersilisifikasi sebagai eksipien
HR20000142A HRP20000142B1 (en) 1997-09-19 2000-03-13 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
IS5404A IS5404A (is) 1997-09-19 2000-03-14 Lyfjablanda sem inniheldur klódrónat sem virkt innihaldsefni og síliseraðan örkristallaðan sellulósa sem burðarefni
NO20001417A NO327728B1 (no) 1997-09-19 2000-03-17 Farmasoytisk preparat omfattende klodronat som aktiv bestanddel samt silisifiert mikrokrystallinsk cellulose som eksipient
BG104265A BG64886B1 (bg) 1997-09-19 2000-03-22 Фармацевтичен препарат, съдържащ клодронат като активен компонент и силикатизирана микрокристална целулоза като пълнител
HK01100766A HK1031325A1 (en) 1997-09-19 2001-02-02 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI973733A FI109088B (fi) 1997-09-19 1997-09-19 Tabletti ja menetelmä sen valmistamiseksi
FI973733 1997-09-19

Publications (3)

Publication Number Publication Date
FI973733A0 true FI973733A0 (fi) 1997-09-19
FI973733A FI973733A (fi) 1999-03-20
FI109088B FI109088B (fi) 2002-05-31

Family

ID=8549561

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973733A FI109088B (fi) 1997-09-19 1997-09-19 Tabletti ja menetelmä sen valmistamiseksi

Country Status (31)

Country Link
EP (1) EP1027037B1 (fi)
JP (1) JP3589977B2 (fi)
KR (1) KR20010024184A (fi)
CN (1) CN1124130C (fi)
AT (1) ATE255410T1 (fi)
AU (1) AU737738B2 (fi)
BG (1) BG64886B1 (fi)
BR (1) BR9812480A (fi)
CA (1) CA2301185C (fi)
CZ (1) CZ298675B6 (fi)
DE (3) DE29824938U1 (fi)
DK (1) DK1027037T3 (fi)
EA (1) EA002331B1 (fi)
EE (1) EE04218B1 (fi)
ES (1) ES2212341T3 (fi)
FI (1) FI109088B (fi)
HK (1) HK1031325A1 (fi)
HR (1) HRP20000142B1 (fi)
HU (1) HU226118B1 (fi)
ID (1) ID24423A (fi)
IL (1) IL135130A (fi)
IS (1) IS5404A (fi)
NO (1) NO327728B1 (fi)
NZ (1) NZ503766A (fi)
PL (1) PL191166B1 (fi)
PT (1) PT1027037E (fi)
SI (1) SI1027037T1 (fi)
SK (1) SK284088B6 (fi)
TR (1) TR200000722T2 (fi)
UA (1) UA73078C2 (fi)
WO (1) WO1999015155A1 (fi)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395303B1 (en) 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
DE10006125C2 (de) * 2000-02-11 2003-08-28 Kallies Feinchemie Ag Modifizierte Mikrocellulose
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
RU2288722C2 (ru) * 2000-06-20 2006-12-10 Новартис Аг Способ введения бисфосфонатов
NZ523086A (en) 2000-06-20 2007-07-27 Novartis Ag Method of administering bisphosphonates
US6753017B2 (en) 2001-11-07 2004-06-22 Jrs Pharma Lp Process for preparing dry extracts
WO2003047551A1 (en) * 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20040109889A1 (en) 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US8491930B2 (en) * 2008-04-23 2013-07-23 Farmasierra Manufacturing, S.L. Pharmaceutical formulation containing ibuprofen and codeine
US8603527B2 (en) * 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
CN114146079A (zh) * 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US20150051175A1 (en) * 2012-05-14 2015-02-19 Antecip Bioventures Ii Llc Co-Administration of Steroids and Zoledronic Acid to Prevent and Treat Pain
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US8865757B1 (en) 2014-05-28 2014-10-21 Antecip Bioventures Ii Llp Therapeutic compositions comprising imidazole and imidazolium compounds
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US8802658B2 (en) 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
CN102671200B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 低聚异麦芽糖片剂赋形剂、药物片剂及制备方法
CN102697744B (zh) * 2012-05-29 2013-11-27 安吉东来药用辅料有限责任公司 阿洛糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102671205B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 紫菜多糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102698280B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 塔格糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102671206B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 低聚果糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102698281B (zh) * 2012-05-29 2013-07-03 安吉东来药用辅料有限责任公司 海带多糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102671203B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 裙带菜多糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102671204B (zh) * 2012-05-29 2013-07-10 安吉东来药用辅料有限责任公司 古洛糖片剂赋形剂、药物片剂及药物片剂的制备方法
CN102688206B (zh) * 2012-05-29 2014-08-20 石药集团中奇制药技术（石家庄）有限公司 一种匹伐他汀钙片及其制备方法
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
AU2015328414B2 (en) 2014-10-06 2020-03-19 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CN104771761A (zh) * 2015-03-19 2015-07-15 深圳国源国药有限公司 一种创新药用辅料硅化微晶纤维素及其制备方法
AU2017240050B2 (en) 2016-04-01 2021-12-16 Signal Pharmaceuticals, Llc Solid forms of (1s,4s)-4-(2-(((3S4R)-3-fluorotetrahydro-2H-pyran-4-yl) amino)-8-((2,4,6-trichlorophenyl) amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
WO2017173206A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
AU2018345647A1 (en) 2017-10-04 2020-04-16 Celgene Corporation Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide
CN111417634A (zh) 2017-10-04 2020-07-14 细胞基因公司 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法
CN110787140A (zh) * 2018-08-01 2020-02-14 北京万全德众医药生物技术有限公司 比拉斯汀片剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3767998D1 (de) * 1986-12-20 1991-03-14 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
HU220872B1 (en) * 1993-05-15 2002-06-29 Roche Diagnostics Gmbh Tablets containing dichloromethylene diphosphonic acid as active agent with enhanced bioavailability and process for producing them
FI94926C (fi) * 1993-11-12 1995-11-27 Leiras Oy Menetelmä klodronaattivalmisteen valmistamiseksi
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability

Also Published As

Publication number Publication date
HU226118B1 (en) 2008-04-28
ES2212341T3 (es) 2004-07-16
JP3589977B2 (ja) 2004-11-17
CN1124130C (zh) 2003-10-15
CN1270516A (zh) 2000-10-18
EA200000317A1 (ru) 2000-10-30
FI973733A (fi) 1999-03-20
DE29824938U1 (de) 2003-07-31
HRP20000142A2 (en) 2000-06-30
EE200000096A (et) 2000-12-15
PL191166B1 (pl) 2006-03-31
ID24423A (id) 2000-07-20
PL339290A1 (en) 2000-12-04
CA2301185C (en) 2006-11-28
CZ2000787A3 (cs) 2000-08-16
ATE255410T1 (de) 2003-12-15
HUP0004383A3 (en) 2006-06-28
PT1027037E (pt) 2004-04-30
DE1027037T1 (de) 2002-11-28
AU9268598A (en) 1999-04-12
HK1031325A1 (en) 2001-06-15
DE69820287T2 (de) 2004-10-14
IS5404A (is) 2000-03-14
EP1027037B1 (en) 2003-12-03
BG104265A (en) 2000-11-30
CZ298675B6 (cs) 2007-12-19
DK1027037T3 (da) 2004-03-15
EP1027037A1 (en) 2000-08-16
IL135130A (en) 2004-09-27
SI1027037T1 (en) 2004-04-30
CA2301185A1 (en) 1999-04-01
EE04218B1 (et) 2004-02-16
NZ503766A (en) 2002-02-01
NO20001417L (no) 2000-05-19
SK3932000A3 (en) 2000-11-07
UA73078C2 (uk) 2005-06-15
JP2001517616A (ja) 2001-10-09
HRP20000142B1 (en) 2004-06-30
BR9812480A (pt) 2000-09-26
EA002331B1 (ru) 2002-04-25
DE69820287D1 (de) 2004-01-15
HUP0004383A2 (hu) 2001-08-28
TR200000722T2 (tr) 2000-11-21
WO1999015155A1 (en) 1999-04-01
NO327728B1 (no) 2009-09-14
NO20001417D0 (no) 2000-03-17
IL135130A0 (en) 2001-05-20
FI109088B (fi) 2002-05-31
SK284088B6 (sk) 2004-09-08
AU737738B2 (en) 2001-08-30
BG64886B1 (bg) 2006-08-31
KR20010024184A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
FI973733A0 (fi) Farmaceutiskt preparat och foerfarande foer dess framstaellning
ATE306261T1 (de) Antithrombosemittel
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
ES2037385T3 (es) Un procedimiento de manufactura de una preparacion farmaceutica para administracion local.
SE9700885D0 (sv) New pharmaceutical formulation
NO995843D0 (no) Farmasöytisk preparat omfattende vWF-propeptid
IS3789A7 (is) Aðferð við framleiðslu lyfjaskammta í föstu formimeð tempraðri losun virks þáttar
DK1105105T3 (da) Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
AU7270798A (en) Antithrombotic agents
NO167861C (no) Analogifremgangsmaate for fremstilling av en ny, terapeutisk aktiv indolokinolinforbindelse.
BG104981A (en) Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
AU7470098A (en) Antithrombotic agents
PT989994E (pt) Derivados de estreptograminas, a sua preparacao e as composicoes que os contem
TNSN99158A1 (ar) طريقة لمنع الاصابة بالربو
NO20014889L (no) Fremgangsmåte for fremstilling av medisinske midler
ATE268768T1 (de) Antithrombosemittel
IT1297140B1 (it) Forma cristallina del guaiacil estere dell'acido l-metil-5-p-toluoil- pirrol-2-acetammidoacetico, procedimento per la sua preparazione e
MX9606264A (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol como sustancias farmacologicas activas.
UY24851A1 (es) Derivados de ácidos n-acil-alfa-aminados
SE9901338D0 (sv) Novel process

Legal Events

Date Code Title Description
SPCL Withdrawal, rejection or dismissal of a supplementary protection certificate

Spc suppl protection certif: L20020014

PC Transfer of assignment of patent

Owner name: BAYER SCHERING PHARMA OY

Free format text: BAYER SCHERING PHARMA OY

MA Patent expired